## 510(k) SUMMARY OF SAFETY AND EFFECTIVENESS

## Explant™ Osteonecrosis Intervention Implant Removal Kit

Submitter Name

Zimmer Trabecular Metal Technology, Inc.

And Address:

80 Commerce Drive

Allendale, New Jersey 07401-1600

Contact Person:

Marci Halevi

**Phone Number:** 

(201) 818-1800

Fax Number:

(973) 829-0825

**Date Prepared:** 

May 4, 2005

**Device Trade Name:** 

The Explant™ Osteonecrosis Intervention Implant Removal

Kit

**Device Common Name:** 

Explant Instruments

**Classification Number** 

and Name:

21CFR878.4820 General and Plastic Surgery Devices

## Substantial Equivalence:

The term "substantial equivalence" as used in this 510(k) notification is limited to the definition of substantial equivalence found in the Federal Food, Drug and Cosmetic Act, as amended and as applied under 21 CFR 807, Subpart E under which a device can be marketed without premarket approval or reclassification. A determination of substantial equivalency under this notification is not intended to have any bearing whatsoever on the resolution of patent infringement suits or any other patent matters. No statements related to, or in support of substantial equivalence herein shall be construed as an admission against interest under the US Patent Laws or their application by the courts.

Device Description:

The instruments are supplied sterile in a preassembled kit. Two size kits are available; a 10mm ID kit and a 14mm ID kit. The 10mm kit cannot be used alone and must be used in combination with the 14mm kit. The instrument come preassembled to Zimmer Hudson Fitting Adaptors, allowing the Tubes to be driven via a Zimmer T-Handle or a Zimmer Power Driver. The Hudson fittings can be removed to expose a through-hole at the end of the tube to allow for removal of a specimen that remains in the coring tube. All components of these kits are single use only.

May 4, 2005 APPENDIX

Indications for Use:

The *Explant™ Osteonecrosis Intervention Implant Removal Kit* is intended for removal of a Trabecular Metal™ Osteonecrosis Intervention Implant.

Device Technological Characteristics and Comparison to Predicate Device: A comparison of device technological characteristics and properties demonstrates that the device is substantial equivalent to the cited predicate devices.

Conclusion:

The *Explant™ Osteonecrosis Intervention Implant Removal Kit* is substantially equivalent to the predicate devices identified in this premarket notification.



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

MAY 2 6 2005

Ms. Marci Halevi Manager of Regulatory Affairs Zimmer Trabecular Metal Technology Incorporated 80 Commerce Drive Allendale, New Jersey 07401

Re: K050766

Trade/Device Name: Explant® Osteonecrosis Intervention Implant Removal

Regulation Number: 21 CFR 878.4820

Regulation Name: Surgical instrument motors and accessories/attachments

Regulatory Class: I Product Code: HWE Dated: March 23, 2005 Received: March 25, 2005

Dear Ms. Halevi:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <a href="http://www.fda.gov/cdrh/industry/support/index.html">http://www.fda.gov/cdrh/industry/support/index.html</a>.

Sincerely, yours,

Miriam C. Provost, Ph.D.

Acting Director

Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and

Radiological Health

Enclosure

## **Indications for Use**

510(k) Number (if known): <b>K050766</b>	
Device Name: Kit	Explant® Osteonecrosis Intervention Implant Removal
	he Explant® Osteonecrosis Intervention Implant for removal of a Trabecular Metal™ Osteonecrosis
Prescription Use	_ AND/OR Over-The-Counter Use  (21 CFR 807 Subpart C)  TE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF
Lividion Lividion LLS IVen	e of CDRH, Office of Device Evaluation (ODE)  (Control of General, Restorative rological Devices  (Cost Cost Cost Cost Cost Cost Cost Cost